PSTV
PLUS THERAPEUTICS, INC.
Next earnings Aug 12, 2026 · consensus $-0.89 EPS, $1.39M rev
Last earnings -8.9% on 2026-05-15
$4.23
▼ -0.82%$4.23▼ -6.11%
over 1Y
L $2.92EODHDH $22.25
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.8%
1W+5.5%
1M-36.7%
3M-27.0%
YTD-70.0%
1Y-6.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Revenue fell -10.5% YoY.
Revenue (FY2025) $5.21M · FY2025
PLUS THERAPEUTICS, INC. shows $5.21M in FY2025 revenue (-10.5% YoY), a -429.4% net margin, and -560.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $4.91M | $5.82M | $5.21M |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| Net income | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Diluted EPS | -$1.11 | -$11.58 | -$4.24 | -$2.34 | -$0.29 |
| Net margin | — | — | -271.0% | -222.8% | -429.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$728M
EV / EBITDA—
EV / Sales139.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.1%
FCF yield-2.9%
Quality & risk
ROIC (est.)-102.8%
Free cash flow-$20.8M
Total debt$7.76M
Net cash-$3.51M
Altman Z-Score-11.53 distress
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+909.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Material agreement2026-06-05
- S-3/A Shelf registration (potential raise)2026-06-05
- S-3 Shelf registration (potential raise)2026-06-02
- 8-K Shareholder vote2026-05-15
- 8-K Earnings results2026-05-15
- 10-Q Quarterly report2026-05-15
- 8-K Other event2026-04-21
- 8-K Officer / director change2026-04-09
- 8-K Other event2026-04-08
Recent filings
all on EDGAR ↗S-8Filing2026-06-18open ↗EFFECTFiling2026-06-05open ↗8-KPeriod ending 2026-06-012026-06-05open ↗S-3/AFiling2026-06-05open ↗S-3Filing2026-06-02open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗
Frequently asked
- Is PLUS THERAPEUTICS, INC. (PSTV) a buy?
- PSTV currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -10.5% YoY.
- What is PLUS THERAPEUTICS, INC.'s quality score?
- PSTV scores 26.843137254901958/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001095981, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 1:19:21 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.